LSP
ALGEMENE INFORMATIE
Bezoekadres
Johannes Vermeerplein 9
1071 DV AMSTERDAM
Tel: 020 664 55 00
Fax: 020 676 88 10 Contactpersoon
Martijn Kleijwegt
René Kuijten
Directie
Martijn Kleijwegt, René Kuijten, Joachim Rothe, Mark Wegter
Johannes Vermeerplein 9
1071 DV AMSTERDAM
Tel: 020 664 55 00
Fax: 020 676 88 10 Contactpersoon
Martijn Kleijwegt
René Kuijten
Directie
Martijn Kleijwegt, René Kuijten, Joachim Rothe, Mark Wegter
LSP is one of the world’s largest specialized healthcare and biotechnology investment firms with aprox. EUR 500 mln. of funds. With a history going back to the late eighties, LSP has grown into a global firm with offices in Amsterdam, Munich and Boston. The LSP team consists of dedicated investment professionals who seek investments both in Europe and the US across the entire spectrum of private and publicly-traded life science companies.
Our investment approach is based on fundamental and independent research and analysis. The LSP investment team is made up of people with relevant backgrounds in a wide range of healthcare and biotechnology disciplines, covering medical, scientific, pharmaceutical, regulatory, clinical, technical and commercial aspects.
The team is supported by a global network of advisors and experts all of whom bring specific expertise essential for performing in-to-depth due diligence on potential investee companies. Our rigorous investment philosophy and sector specialization offer our shareholders access to a high growth and high potential sector in which LSP has built a proven 20 year investment track record.
Our investment approach is based on fundamental and independent research and analysis. The LSP investment team is made up of people with relevant backgrounds in a wide range of healthcare and biotechnology disciplines, covering medical, scientific, pharmaceutical, regulatory, clinical, technical and commercial aspects.
The team is supported by a global network of advisors and experts all of whom bring specific expertise essential for performing in-to-depth due diligence on potential investee companies. Our rigorous investment philosophy and sector specialization offer our shareholders access to a high growth and high potential sector in which LSP has built a proven 20 year investment track record.
PROFIEL
- Sectoren/branches
- Life Sciences
- Financieringsfasen
- Expansie
- Seed
- Start
- Investering
- 2 mln - 5 mln
- 5 mln - 20 mln
- Regio's
- Europa
- Nederland (excl. regionale focus)
- Verenigde Staten
- Belegger in fonds
- Banken
- Fonds in Fonds
- Niet-financiële instellingen
- Overig
- Pensioenfondsen
- Verzekeringsmaatschappijen
INVESTERINGEN
| bedrijf | jaar | sector | fase |
|---|---|---|---|
| QIAGEN | 1989 | ontwikkeling moleculaire tests | Beursgenoteerd |
| Pharming | 1990 | Drug development and protein production from milk from transgenic cows and rabbits | Early Stage |
| Jerini | 1994 | Healthcare | Early Stage |
| OctoPlus | 1996 | drug development | Early Stage |
| Activaero | 1998 | Inhalation devices for controlled pulmonary drug delivery and clinical reprofiling and development of pulmonary drugs in various indications. | Growth |
| Sequenom | 1998 | drug development | Early Stage |
| Zealand Pharma | 1998 | drug development | Early Stage |
| Crucell | 1999 | Biotechnology company with a focus on commercialization of its protein production platform (PER.C6) | Beursgenoteerd |
| Devgen | 1999 | biotechnology | Early Stage |
| Santarus | 1999 | Pharmaceuticals | Beursgenoteerd |
| Isto | 2000 | orthobiologic company | Early Stage |
| Kreatech | 2000 | Biotechnologie | Early Stage |
| PamGene | 2000 | Biotechnologie | Early Stage |
| Kiadis Pharma B.V. | 2001 | Biotechnologie | Early Stage |
| Seahorse Bioscience Inc. | 2001 | Seahorse Bioscience provides industry-leading analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. | Early Stage |
| BioXell | 2002 | Biopharmaceutical company developing new therapeutic candidates in the areas of urology and inflammation, using its unique expertise in Vitamin D3 chemistry and biology. | Beursgenoteerd |
| Cosmo Pharmaceuticals | 2002 | Biotechnologie | Early Stage |
| Hybrigenics | 2002 | Company with an internal clinical pipeline in oncology and a service business based on its high throughput technology and bioinformatics platforms to identify, validate and inhibit protein interactions. | Early Stage |
| Affectis (vh. NeuroNova) | 2003 | bio-pharmaceutisch bedrijf | Early Stage |
| Innovative BioSensors (IBI) | 2003 | Company developing and manufacturing rapid testing systems for the detection of pathogens at high levels of sensitivity and specificity | Growth |
| MDx Health | 2003 | diagnostics | Early Stage |
| 4-Antibody GmbH | 2004 | Company generating high affinity, fully human monoclonal antibodies. | Early Stage |
| Atlas Genetics | 2005 | Diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases using either nucleic acid or immuno-assays. It is based on a patent protected electrochemical sensor that combines speed and accuracy | Early Stage |
| Bmeye | 2005 | cardiovascular monitoring devices | Early Stage |
| IDEA | 2005 | Healthcare | Early Stage |
| ActoGenix | 2006 | Biotechnology, therapeutics | Early Stage |
| Attune Foods Inc. | 2006 | All-natural daily wellness bars that balances the digestive system | Early Stage |
| Efficas Inc. | 2006 | Development of bioactive products for nutritional management of specific health conditions related to immune system | Early Stage |
| Eyesense | 2006 | Healthcare | Early Stage |
| Mendor | 2006 | Company marketing discreet all-in-one blood glucose meter for diabetes patients | Growth |
| Movetis | 2006 | Drug development company with a clinical portfolio targeting gastro-intestinal disorders including a marketed product for the treatment of chronic constipation | Beursgenoteerd |
| Pronota | 2006 | Company focusing on the discovery of protein biomarkers for molecular diagnostics both for early detection of disease and for responder/non-responder identification | Early Stage |
| Trinity Biosystems | 2006 | Developing oral protein therapeutics and vaccins based on proprietary transmucosal protein delivery technology | Early Stage |
| Affimed Therapeutics AG | 2007 | Development of recombinant antibodies | Early Stage |
| Harvest Automation, Inc. | 2007 | Harvest Automation provides agile mobile robots (AMR) platforms for material handling. AMR platforms are low cost independent robots which target direct labor replacement in applications such as nursery and greenhouse markets. | Growth |
| Nexstim | 2007 | werking van de hersenschors scannen | Early Stage |
| Okairos AG | 2007 | Genetic vaccins for treatment of chronic infectious diseases | Early Stage |
| Pasteuria Bioscience | 2007 | Biotechnologie | Early Stage |
| Prosensa | 2007 | Biotechnologie | Early Stage |
| Skyline Diagnostics | 2007 | Biotechnologie, diagnostic tools for cancer | Early Stage |
| Syntaxin | 2007 | Biotechnologie | Early Stage |
| Tigenix | 2007 | development of cellular therapeutics for gastrointestinal and urology indications | Early Stage |
| Asoyia Inc., | 2008 | productie soyabonen | Early Stage |
| COBALT BIOFUELS | 2008 | ontwikkeling van biobutanol | Growth |
| arGEN-X | 2009 | Company developing full-length, monoclonal antibodies generated by its proprietary SIMPLE Antibody™ platform. | Early Stage |
| Curetis AG | 2009 | moleculaire diagnoses | Early Stage |
| Probiodrug | 2009 | Company developing new drugs for the treatment of diseases such as pain/inflammation and Alzheimer’s disease | Early Stage |
| Merus | 2010 | biopharmaceutisch | Early Stage |
| Sapiens Steering Brain Stimulation | 2011 | Company developing deep brain stimulation for treatment of Parkinson’s Disease | Early Stage |
